DYN - Dyne Therapeutics Year-over-year earnings per share growth for the last twelve months

Dyne Pharma - graphic logo of issuer DYN

The development of a lifelong therapy for muscular dystrophies ensures sales stability for Dyne Therapeutics, Inc. (DYN). The intensity of quarterly EPS growth visualizes this potential, where the -40.40 mark characterizes this parameter. Complex patents for oligonucleotide delivery strengthen the business foundation, creating high barriers to entry. However, access to global capital and clinics remains sensitive to geopolitical risks.

Dyne Therapeutics (DYN) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Dyne Therapeutics (DYN)

- market value and analyst target forecast:
- market capitalization statistics:
Comprehensive company analysis:Dyne Therapeutics, Inc. - DYN
Flagship merchandise of dyne-tx.com

Asset managers evaluate the operational efficiency of Dyne Therapeutics, Inc. (DYN) through net income dynamics. This metric measures the percentage change in earnings per share between the current and previous quarter. By analyzing the growth rate of quarterly earnings per share, investors identify the gap between market expectations and actual returns. While molecular design automation accelerates development, slow clinical trials constrain growth. The stability of this indicator confirms the fundamental resilience of the business.

Key competitors

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|EWTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata